Published in Dig Dis on December 17, 2014
Familial adenomatous polyposis in China. Oncol Lett (2016) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46
The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut (2001) 10.07
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med (1993) 6.13
Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology (2012) 3.83
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2008) 3.76
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med (2002) 3.16
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology (2011) 3.08
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol (2005) 2.98
CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest (2003) 2.97
Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology (2013) 2.97
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut (2013) 2.86
Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology (1992) 2.86
Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 2.80
Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology (2013) 2.78
The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nat Med (1999) 2.76
Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol (2012) 2.73
Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg (1993) 2.70
Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. J Natl Cancer Inst (1989) 2.60
Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol (2008) 2.47
Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology (1991) 2.43
5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol (2011) 2.41
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol (2011) 2.38
Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol (2008) 2.25
Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut (2010) 2.23
Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med (2001) 2.22
Familial adenomatous polyposis. Orphanet J Rare Dis (2009) 2.21
Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther (2006) 2.12
Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol (2005) 1.95
Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1996) 1.82
Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut (2011) 1.74
A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) (2011) 1.64
5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology (2006) 1.62
5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol (2012) 1.61
Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol (2006) 1.57
High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther (2012) 1.49
Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology (2002) 1.45
The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology (2004) 1.41
Frequency of hereditary colorectal carcinoma. Gastroenterology (1987) 1.35
Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology (1999) 1.35
Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis (2013) 1.31
5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut (2005) 1.29
Hereditary nonpolyposis colorectal cancer (Lynch syndromes I & II). Genetics, pathology, natural history, and cancer control, Part I. Cancer Genet Cytogenet (1991) 1.21
A randomized trial of ascorbic acid in polyposis coli. Cancer (1982) 1.20
The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology (1997) 1.19
Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol (2013) 1.18
The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther (2005) 1.13
Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer? J Surg Oncol (2000) 1.12
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis (2008) 1.09
Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology (1990) 1.09
The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol (2010) 1.08
Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology (1994) 1.07
Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy (2000) 1.07
Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol (2010) 1.07
Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncol (2012) 1.01
Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Cancer (2002) 0.98
Rectal cancer after prolonged sulindac chemoprevention. A case report. Cancer (1995) 0.98
Mesalazine improves replication fidelity in cultured colorectal cells. Cancer Res (2005) 0.93
Omega-3 polyunsaturated fatty acids. Best Pract Res Clin Gastroenterol (2011) 0.93
Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci (2013) 0.92
The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis (1993) 0.90
Oral calcium inhibits rectal epithelial proliferation in familial adenomatous polyposis. Br J Surg (1993) 0.89
Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochem Pharmacol (2012) 0.88
Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One (2014) 0.87
Chemoprevention in Lynch syndrome. Fam Cancer (2013) 0.86
Extracolonic manifestations of hereditary colorectal cancer syndromes. Clin Colon Rectal Surg (2008) 0.85
Curcumin: the potential for efficacy in gastrointestinal diseases. Best Pract Res Clin Gastroenterol (2011) 0.85
5-Aminosalicylic acid inhibits TGF-beta1 signalling in colorectal cancer cells. Cancer Lett (2009) 0.85
Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis. Dis Colon Rectum (2001) 0.84
Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med (2013) 0.84
Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis. J Gastroenterol Hepatol (2006) 0.83
Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment Pharmacol Ther (2008) 0.83
Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis. PLoS One (2013) 0.83
Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis. Dig Dis Sci (2013) 0.82
Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats. Clin Cancer Res (2010) 0.81
Effect of ascorbic acid on rectal polyps of patients with familial polyposis. Surgery (1975) 0.81
Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial. Int J Clin Oncol (2006) 0.81
Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. Inflamm Bowel Dis (2007) 0.81
The effect of ursodesoxycholic acid on duodenal adenomas in familial adenomatous polyposis: a prospective randomized placebo-control trial. Colorectal Dis (2012) 0.80
Modulation of N-glycosylation by mesalamine facilitates membranous E-cadherin expression in colon epithelial cells. Biochem Pharmacol (2013) 0.80
Interaction of mesalasine (5-ASA) with translational initiation factors eIF4 partially explains 5-ASA anti-inflammatory and anti-neoplastic activities. Med Chem (2011) 0.78
Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased. Clin Gastroenterol Hepatol (2011) 0.77
Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial. Orphanet J Rare Dis (2013) 0.77
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol (2008) 2.71
FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology (2011) 2.64
Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial. Inflamm Bowel Dis (2013) 2.13
5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology (2006) 1.62
A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res (2003) 1.41
Estimation of spontaneous mutation rates. Biometrics (2003) 1.41
Iron sensing and signalling. Gut (2011) 1.38
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis (2008) 1.09
Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol (2009) 1.07
Pathogenesis and treatment of anemia in inflammatory bowel disease. Haematologica (2010) 1.04
Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 1.03
MSH3-deficiency initiates EMAST without oncogenic transformation of human colon epithelial cells. PLoS One (2012) 1.01
Inflamed gut mucosa: downstream of interleukin-10. Eur J Clin Invest (2011) 0.99
Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. PLoS One (2012) 0.99
Aspirin blocks proliferation in colon cells by inducing a G1 arrest and apoptosis through activation of the checkpoint kinase ATM. Carcinogenesis (2007) 0.89
Differential signaling of cmvIL-10 through common variants of the IL-10 receptor 1. Eur J Immunol (2008) 0.89
Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochem Pharmacol (2012) 0.88
Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling. Mol Cancer (2013) 0.87
The nucleotide composition of microsatellites impacts both replication fidelity and mismatch repair in human colorectal cells. Hum Mol Genet (2010) 0.86
Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries. Eur J Gastroenterol Hepatol (2013) 0.85
Overexpression of PAK1 promotes cell survival in inflammatory bowel diseases and colitis-associated cancer. Inflamm Bowel Dis (2015) 0.83
Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin. Am J Hematol (2014) 0.82
Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats. Clin Cancer Res (2010) 0.81
Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia. Dig Dis Sci (2014) 0.80
Ingested matter affects intestinal lesions in Crohn's disease. Inflamm Bowel Dis (2008) 0.79
[Anemia in chronic inflammatory intestinal disease: an often underestimated problem]. Dtsch Med Wochenschr (2002) 0.79
Homozygosity of the interleukin-10 receptor 1 G330R allele is associated with schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2007) 0.78
Interaction of mesalasine (5-ASA) with translational initiation factors eIF4 partially explains 5-ASA anti-inflammatory and anti-neoplastic activities. Med Chem (2011) 0.78
IL-10RA truncation mutations and Semite populations. Inflamm Bowel Dis (2010) 0.78
Improvement of replication fidelity by certain mesalazine derivatives. Int J Oncol (2012) 0.78
The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelity. Inflamm Bowel Dis (2010) 0.77
NOD2 and colorectal cancer: guilt by non-association. Cancer Res (2004) 0.76
Aminosalicylates. Best Pract Res Clin Gastroenterol (2011) 0.76
Design and instrumentation of new devices for performing appendectomy at colonoscopy (with video). Gastrointest Endosc (2008) 0.75
Tourette's syndrome is not associated with interleukin-10 receptor 1 variants on chromosome 11q23.3. Psychiatry Res (2007) 0.75
Crohn's disease: ingested matter matters. Inflamm Bowel Dis (2010) 0.75
Reply to Zuo et al. Inflamm Bowel Dis (2013) 0.75
HuR Small-Molecule Inhibitor Elicits Differential Effects in Adenomatosis Polyposis and Colorectal Carcinogenesis. Cancer Res (2017) 0.75
A novel endoscopic device for repeated right-side colonic access during colonoscopy (with video). Gastrointest Endosc (2010) 0.75
Assessment of Gaps in Care and the Development of a Care Pathway for Anemia in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis (2016) 0.75
Standard therapy of Crohn's disease. Dig Dis (2003) 0.75
Lack of correlation between IL-10R1 S138G loss-of-function allele and IBD in the Lebanese population. Inflamm Bowel Dis (2010) 0.75
Anatomy of the GI tract in US: an historical perspective. Eur J Gastroenterol Hepatol (2005) 0.75
Inflammatory bowel disease. Int J Inflam (2012) 0.75
Chemoprevention goes gourmet: different flavors of NO-aspirin. Mol Interv (2005) 0.75